



Peptides with Dual Antimicrobial and Anticancer Activities

Mário R. Felício^{1‡}, Osmar N. Silva^{2‡}, Sônia Gonçalves¹, Nuno C. Santos¹ and Octávio L. Franco^{2,3*†}

¹ Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal, ² S-Inova Biotech, Pós-graduação em Biotecnologia, Universidade Católica Dom Bosco, Campo Grande, Brazil, ³ Programa de Pós-Graduação em Patologia Molecular, Universidade de Brasília, Brasília, Brazil

OPEN ACCESS

Edited by:

Neil Martin O'Brien-Simpson, University of Melbourne, Australia

> **Reviewed by:** Yuji Nishiuchi, GlyTech, Inc., Japan

Jonathan Baell, Monash University, Australia

*Correspondence: Octávio L. Franco ocfranco@gmail.com

[†]Present Address:

Octávio L. Franco, Pós-graduação em Ciências Genômicas e Biotecnologia, Centro de Análises Proteômicas e Bioquímicas, Universidade Católica de Brasília, Brasília, Brasília, Brasília

[‡]These authors have contributed equally to this work.

Specialty section:

This article was submitted to Chemical Biology, a section of the journal Frontiers in Chemistry

Received: 14 December 2016 Accepted: 06 February 2017 Published: 21 February 2017

Citation:

Felício MR, Silva ON, Gonçalves S, Santos NC and Franco OL (2017) Peptides with Dual Antimicrobial and Anticancer Activities. Front. Chem. 5:5. doi: 10.3389/fchem.2017.00005 In recent years, the number of people suffering from cancer and multi-resistant infections has increased, such that both diseases are already seen as current and future major causes of death. Moreover, chronic infections are one of the main causes of cancer, due to the instability in the immune system that allows cancer cells to proliferate. Likewise, the physical debility associated with cancer or with anticancer therapy itself often paves the way for opportunistic infections. It is urgent to develop new therapeutic methods, with higher efficiency and lower side effects. Antimicrobial peptides (AMPs) are found in the innate immune system of a wide range of organisms. Identified as the most promising alternative to conventional molecules used nowadays against infections, some of them have been shown to have dual activity, both as antimicrobial and anticancer peptides (ACPs). Highly cationic and amphipathic, they have demonstrated efficacy against both conditions, with the number of nature-driven or synthetically designed peptides increasing year by year. With similar properties, AMPs that can also act as ACPs are viewed as future chemotherapeutic drugs, with the advantage of low propensity to resistance, which started this paradigm in the pharmaceutical market. These peptides have already been described as molecules presenting killing mechanisms at the membrane level, but also acting toward intracellular targets, which increases their success compartively to one-target specific drugs. This review will approach the desirable characteristics of small peptides that demonstrated dual activity against microbial infections and cancer, as well as the peptides engaged in clinical trials.

Keywords: anticancer peptides (ACPs), antimicrobial peptides (AMPs), cancer, multi-resistant infections, bacteria

INTRODUCTION

At the beginning of the twenty-first century, the increased appearances of multi-resistant bacterial pathogens have become a worldwide problem (Arias and Murray, 2009). The World Health Organization has already emphasized the urgency in designing new antimicrobial molecules, because conventional antibiotics are increasingly useless as therapeutics, especially against the so-called *ESKAPE* pathogens (*Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa,* and *Enterobacter* species), which showed a high propensity to develop antibiotic resistance (McKenna, 2013). Another global concern is the rise in the incidence of cancer. Recent data released revealed 12.7 million new cases and 7.6 million deaths, just in 2008 (Ferlay et al., 2010). In Europe alone, 3.45 million new cases were diagnosed and 1.75

1

million deaths occurred during 2012 (Ferlay et al., 2013). Nowadays, cancer is the second most common cause of death worldwide (Arnold et al., 2015), caused by an abnormal cellular growth, in a uncontrolled manner, with the ability to invade other tissues, leading to the formation of tumor masses, neovascularization (angiogenesis), and metastasis (Thundimadathil, 2012). Lung, colorectal, prostate, and breast cancer are the most diagnosed forms of this disease (Domalaon et al., 2016). Considering the numbers revealed, it is urgent to find new anticancer drugs able to control tumor growth with minimal side effects (Dennison et al., 2007). This situation has become worse due to DNA-alkylation, hormone agonists, and antimetabolites, which show insufficient selectivity and unspecific targeting on healthy cells (Smith and White, 1995; Gaspar et al., 2013), contributing to increased resistance to anticancer drugs (Wang K.-r. et al., 2009). Moreover, the intersection between infection and cancer is highlighted by the number of cancer deaths and new occurrences that are related to treatment or chronic infections. Approximately 2 million of the new cancer patients are due to infectious agents like bacteria and viruses (Parkin, 2006; Attiê, 2014; Vedham et al., 2014). Patients that suffer from a chronic infection are more susceptible to cancer due to the weakened immune system, which cannot fight both the pathogen, and the emergence of cancer cells (Rolston, 2001). This weakness can also occur due to cancer treatments that are too aggressive to patient health, such as chemotherapy, radiotherapy, and surgical resection, leaving patients susceptible to infection agents (Fishman, 2011; Xiao et al., 2015). Also, continuous exposure to infection leads to inflammation, contributing to the appearance of cancer (Vedham et al., 2014).

In recent years, a promising new class of molecules has arisen, and it has different types of advantages against both of the above major world health concerns. Antimicrobial peptides (AMPs) are small peptides essential for the innate immune response of organisms of all branches, presenting activity against a wide range of pathogens, like bacteria, fungi, and viruses (Hancock et al., 2016). More recently, anticancer activity was also described for some of these peptides, termed anticancer peptides (ACPs) (Dennison et al., 2006). Properties like their short time-frame of interaction (which decreases the probability of resistance), low toxicity (which reduces side effects), mode of action, specificity, good solubility, and finally, good tumor penetration, indicate ACPs as a future chemotherapy cancer drug with high potential (Riedl et al., 2011; Figueiredo et al., 2014; Wu et al., 2014; Gaspar et al., 2015; Domalaon et al., 2016).

PEPTIDES WITH ANTIMICROBIAL AND ANTICANCER ACTIVITY

Antimicrobial peptides were first identified due to their importance in the innate immunity of a broad number of organisms, gaining interest from the scientific community (Jenssen et al., 2006). From the first identification until today, hundreds of AMPs have been identified and studied, either from natural sources or from *in silico* designs (Hancock et al., 2016). These peptides are characterized by an amino acid sequence usually from 5 to 50 residues, high hydrophobicity and positive net charge (Melo et al., 2011; Gaspar et al., 2012). These physicochemical properties set the basis for the activity against pathogens (Dennison et al., 2010). Bacteria present negatively charged membranes, promoting AMPs' initial electrostatic interaction. Even knowing that not all AMPs are ACPs, the similarity in terms of action is obvious, due to the phenotype of the membrane surface in cancer cells. In the plasma membrane inner-leaflet of healthy cells there is phosphatidylserine (PS), a negatively charged phospholipid. This asymmetry between inner and outer membrane leaflets is lost in cancer cells, leading to the presence of PS in the outerleaflet (Bevers et al., 1996). PS exposure, the presence of Oglycosylated mucins, sialylated gangliosides, and heparin sulfate, in conjugation with an increased transmembrane potential, surface area, and membrane fluidity (Schweizer, 2009; Hilchie et al., 2011), promote the specific activity of AMPs toward cancer cells (ACPs), without being affected by tumors' heterogeneity (Kelly et al., 2016).

The physicochemical parameters determining the activity of some AMPs toward cancer cells are still unclear, considering that the characteristics of AMPs/ACPs are very similar. Efforts are being made in order to understand these differences, which would enable an improved design of ACPs (Dennison et al., 2006). Some AMPs can also be ACPs independently of the source of identification or synthetic route of design (Mader and Hoskin, 2006). The number of AMPs encountered in nature that have anticancer activity has increased in recent years. Aurein 1.2 (GLFDIIKKIAESF), a peptide isolated from the frog Litoria aurea, is one example of an AMP with broad-range activity toward bacteria that showed to be highly active toward 55 different cancer cell lines in vitro, without any significant cytotoxic activity (Rozek et al., 2000; Dennison et al., 2007; Giacometti et al., 2007). Another example is the human neutrophil peptide-1 (HNP-1, ACYCRIPACIAGERRYGTCIYQGALWAFCC), an AMP that plays a fundamental role in the defense against pathogens in the innate immune system. Its antimicrobial activity has been fully explored, with a broad spectrum activity against bacteria, but it is the possibility of using this AMP in cancer therapies that attracted attention in recent years (Nishimura et al., 2004; Varkey and Nagaraj, 2005). The full mechanism of action of this peptide against cancer cells has not yet been established, but activity was already confirmed for different cancer cell lines, with very low cytotoxicity against healthy cells (McKeown et al., 2006; Gaspar et al., 2015). Peptides pleuricidin 03 (GRRKRKWLRRIGKGVKIIGGAALDHL) and pleuricidin (RWGKWFKKATHVGKHVGKAALTAYL), 07 AMPs isolated from Atlantic flatfishes, were showed to be highly effective in killing different bacterial strains (Patrzykat et al., 2003). Recently, their anticancer activity was explored and their effectiveness against drug-resistant breast cancer cells confirmed, without toxicity against fibroblasts or erythrocytes, either in in vitro and in vivo models (Hilchie et al., 2011). These are just examples of ACPs that were studied after isolation from different natural sources, like animals, plants, and bacteria. Natural ACPs, even having a high anticancer activity, have

normally 30-40 amino acids in their sequence, which increases production costs. Therefore, synthetic routes for ACP design have gained attention. There are different possible approaches available, such as the improvement of natural ACP sequences or the use of in silico methods (Park et al., 1998; Lee et al., 2008). Both strategies take into consideration the improvement of the physicochemical properties, like amphipathicity, hydrophobicity, and overall positive charge, with the objective of better activity toward the target cells (Huang et al., 2011; Melo et al., 2011; Sinthuvanich et al., 2012). Furthermore, other strategies such as hybridizing different ACPs (Hoskin and Ramamoorthy, 2008) or changing the amino acids used for unnatural ones (D-enantiomers or cyclic tetra-substitution of C^{α} are examples; Hicks, 2016) have also been tested. The possibilities are endless, and depend on what the focus of the improvement is for each case. Bioinformatic algorithms integrated with machine learning, where the design is automatic through the properties chosen, taking into consideration AMP/ACP libraries of existing molecules, are considered the future method for their rational design (Tyagi et al., 2013; Lin et al., 2015).

AMPs and ACPs share most of the characteristics, like the physicochemical properties already described. Structure plays a central role in their activity. It is commonly accepted that most AMPs/ACPs do not fold in a well-defined structure when free in solution, but adopt α -helix or β -sheet structure when electrostatic interactions with membranes occur (Hoskin and Ramamoorthy, 2008). Differences in terms of structure were the first method for the classification of ACPs. Examples of some AMPs lately defined as α-ACPs are cecropin, magainin, melittin, and buforin II, with lactoferricin B, HNP-1/3, and gamesin being classified as β -ACPs (Papo and Shai, 2005). More recently, it was noticed that independently of the secondary structure that the peptide adopts, a classification considering the mechanisms of action in the target cancer cells was more suitable (Wu et al., 2014). AMPs were considered membraneactive peptides regarding their primary activity, but over the years, it was clarified that they can also target different processes of the pathogen (namely, metabolism, and cell division) and of the immune system (recruitment of immune cells; Hancock et al., 2016). These aspects were also studied for ACPs, with the identification of cell membrane lytic activity (necrosis), mitochondrial membrane lytic activity (apoptosis), and nonmembrane activities (Figure 1; Wu et al., 2014). The first one is the most common anticancer method of targeting, with the electrostatic interactions promoting membrane disruption, leading to necrosis. Polybia-MPI, a natural ACP, and the synthetic BTM-P1 are just two examples (Segura et al., 2007; Wang K.-r. et al., 2009). These ACPs have high selectivity toward cancer cell membranes and develop low resistance, when compared to conventional chemotherapeutic drugs. Activity toward mitochondrial membrane, activating apoptosis signaling, was also observed for some ACPs, such as lactoferricin B and different β-ACPs (Furlong et al., 2006; Paredes-Gamero et al., 2012). After the activity at the membrane level, ACPs can also present other activities, either targeting essential cell proteins, inhibiting angiogenesis, or recruiting immune cells to attack cancer cells (Figure 1; Wu et al., 2014). HNP-1 was shown to be an ACP that recruits and activates dendritic cells in terms of immunomodulatory activity (Wang Y.-s. et al., 2009), but also inhibits angiogenesis, which is essential to the growth and development of tumors (Xu et al., 2008).

POTENTIAL CLINICAL APPROACHES USING ACPs

Although a wide variety of drugs are commercially available, treatments for infections, and cancer have one thing in common: the emergence of resistance against multiple drugs (Baguley, 2010; Theuretzbacher, 2012). Another associated problem is the lack of selectivity of the available drugs, and their consequent undesirable side effects for the patients (Mandell et al., 2001; Baguley, 2010). Thus, there is a need for the development of new antineoplastic and antimicrobial therapies, with higher selectivity, leading to fewer side effects than current ones. It is desirable that these new compounds present different mechanisms of action, without dependence on activity toward a single specific molecule in the target cells, like the ones used nowadays in therapeutics. The main goal is resistance prevention, overcoming the existing mechanisms that cancer and bacterial cells use, being active and diminishing the side effects (Lincke et al., 1990; Arias and Murray, 2009; Kakde et al., 2011).

As described earlier, several AMPs and/or ACPs have become the focus of research by different groups, mainly due to their ability to kill or inhibit the growth of a variety of microorganisms and tumor cells (Wu et al., 2014; Hancock et al., 2016). There are thousands of natural peptides and millions of synthetic peptides obtained by rational design, with a large number presenting antimicrobial and anticancer activity, but only a few being tested (Gordon et al., 2005). Furthermore, from these, unfortunately, only a small number are currently in clinical trials (Table 1). This is mostly due to the numerous challenges associated with the development of these peptides as pharmaceutical drugs, such as synthesis costs, which are higher than the synthesis of organic antibiotic small molecules. Due to this, peptide design has focused on primary structure shortening, accomplishing a lower production cost, and allowing physicochemical properties to be easily changed, which is important for the activity of AMPs/ACPs (Tørfoss et al., 2012a; Domalaon et al., 2016).

In addition, the adverse effects presented by some peptides (high toxicity to mammalian healthy cells and low immune response modification) increase the number of obstacles to applying these molecules to therapy (Hancock, 1997; Andreu and Rivas, 1998; Xiao et al., 2015; Kao et al., 2016). This is not surprising, since the activity of AMPs/ACPs usually depends on membrane-peptide interaction. However, to be commercially useful, it would be necessary to dissociate the toxicity to the mammalian cells from antimicrobial/antitumor activity, which can be achieved by increasing antimicrobial activity, reducing haemolytic activity, or both (Chen et al., 2005; Uggerhøj et al., 2015).

Another obstacle to the applicability of peptides is their susceptibility to proteolysis. Oral administration remains



the preferred mode for drug delivery, corresponding to approximately 60% of the administration routes used for drugs (Renukuntla et al., 2013). This occurs due to the advantages that these drugs present, including low production cost and patient compliance in the administration. Even so, peptide drugs usually follow the traditional route of administration, like intramuscular (i.m.) or intravenous (i.v.) injection, due to their poor oral bioavailability, which is expressed by a low resistance to proteases and poor penetration through the intestinal membrane (Hamman et al., 2005). Sensitivity to proteolytic degradation can be mitigated by using rational design to replace naturally occurring amino acids with unnatural ones (Gordon et al., 2005; Uggerhøj et al., 2015). An example is the synthetic design of D-enantiomeric peptides, like DJK-5/6, which show improved activity against bacterial infections in *in vivo* models, comparable to that of the L-enantiomeric peptides, without showing any cytotoxic activity (de la Fuente-Núñez et al., 2015; Mansour et al., 2016). This type of peptide were also shown to be more actively effective against drug-resistant tuberculosis pathogens, and have already been tested with inhalable spray-dried formulations (Lan et al., 2014; Kwok et al., 2015). In terms of ACPs, SVS-1 was seen to be more effective, compared to its L-isomeric peptide form (Sinthuvanich et al., 2012). $\beta^{2,2}$ amino acids, also unnatural ones, can be another strategy to design AMPs/ACPs that are resistant to proteolysis, with a high effectiveness against the target cells and low toxicity toward healthy cells (Tørfoss et al., 2012a,b).

Together with proteolysis comes the limitation of pharmacokinetics and pharmacodynamics, because it is difficult to evaluate the direct action of the peptide against the pathogen in vivo and relate to a specific mode of action (Drusano, 2004). Moreover, the time of circulation, which is essential for a drug to be efficient, is not easy to determine (Kelly et al., 2016). Different strategies have been proposed for this problem, like the use of drug carriers, such as bacteriophages (Dabrowska et al., 2014). Using a natural bacterial phage, displaying ACPs on their surface, increases the targeting (dynamics of action) and allows for improved dual activity. Conjugating the peptide with cell-penetrating peptides (CPPs) can be another interesting strategy to improve the specificity of the targeting. Some authors have used TAT protein from HIV virus as the CPP, conjugated to an AMP/ACP (HPRP-A1) in order to increase the specificity toward cancer cells (Hao et al., 2015). Coating or conjugation of peptides with polymers, like polyethylene glycol (PEG), can also increase circulation and improve pharmacokinetics/dynamics, independently of the polymer used, by allowing a higher time of circulation and improving their penetration toward the target cancer cells (Kelly et al., 2016).

In conclusion, these modifications may promote changes in amphipathic/hydrophobic properties, leading to the reduced cytotoxicity of peptides toward mammalian cells, without jeopardizing antimicrobial/anticancer efficiency, rendering peptides more impervious to proteolysis, and thus bestowing on

sted.	
) tes	
eing	
ē.	
y ar	
the	
lich	
ž	
J foi	
itio	
ond	
ic o	
beut	
erap	
e tř	
d the	
anc	
hase	
t ph	
hes	
hig	
the	
n of	
atio	
Jdic	
Je ir	
th th	
, ĸi	
rials	
al t	
linio	
in c	
des	
epti	
ial p	
robi	
mici	
antir	
pu	
canc	
Anticancer	
1	
ABLE .	
TABI	

Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Preclinical Precl	ANG-4043 AngloChem Co. Precinical 001 M6F-205 AngloChem Co. Precinical 1201 Gathere Pharmaceutcals Inc. I 1201 Gathere Photocon Incernitive Liel Sencess Inc. I 1201 Catrarea Liel Sencess Inc. I I 1201 Catrarea Liel Sencess Inc. I I 1201 Catrarea Liel Sencess Inc. I I 1202 Catrarea Liel Sencess Inc. I I 1203 Incernitive Liel Sences Inc. I I 1204 University of Batord I I 1205 Virume University I I </th <th>ACPs ANG-4043 ∽is mat</th> <th></th> <th></th> <th></th> <th></th> <th></th>	ACPs ANG-4043 ∽is mat					
4NG-4051 AngoOrem Co. Predinced 01 MB-265 Cadenoe Pharmeseutidals Inc. II 201 Catenoe Pharmeseutidals Inc. II Predinced 201 Catenoe Pharmeseutidals Inc. II II 201 Catenoe Pharmeseutidals Inc. II II 201 Catenoe Pharmeseutidals Inc. II II 202 Catona Cagliado Co. Investivy of Badford II CNP ICT04-CVP Incenthera Ltd. II CNP ICT04-CVP Incenthera Ltd. II CNP ICT04-CVP Incenthera Ltd. II CNP Incenthera Ltd. Incenthera Ltd. III CNP Incenthera Ltd. Incenthera Ltd. III CNP Incenthera Ltd. III IIII Control Incenthera Ltd. IIII IIIII CNP Incenthera Ltd. IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII	602 Montal consistent Period Bit measurement 01 Net-dots Constration I Variante measurement 01 Constration I Variante measurement I 01 Constration I Sector Interstation 01 Constration I Sector Interstation 01 Constration I Sector Interstation 02 Constration Interstation Interstation Interstation 03 Constration Interstation Interstation Interstation 03 Constration Interstation Interstation Interstation	ANG-4043					
01 MBI-266 Cadence Pharmeasuticals Inc. II 1201 GRN-1201 Cansus Septial Con: Current Sentence Inc. I 1201 GRN-1201 Cansus Septials Con: Current Postment Inc. I -588 CT01-2588 Incentinea Ltd. I -1 University of Bradroid I I -CVP CT04-CVP Incentinea Ltd. I	01 MB 265 Contron Phrmaceutals Inc. 1 War Integrited recessa 1281 Caran Capati On: Caran Capati On: Memoric 1 Ver Integrited recessa 1281 General Capati On: Caran Capati On: Memoric 1 Sold turnes 1281 Caran Capati On: Caran Capati On: Memoric 1 Sold turnes 258 CT01-286 Internet Lut Non Internet forchinal Unerstry of Station 1 269 CT05-565 Internet Lut Non Internet forchinal Unerstry of Station 1 Sold turnes 261 CT05-565 Internet Juli Non Internet forchinal Unerstry of Station 1 Sold turnes 261 CT05-565 Internet Juli 1 Non Vertical Anne (prediciol Unerstry of Station 271 Unerstry of Station 1 Non Vertical Anne (prediciol Unerstry of Station 273 Unerstry of Station 1 Non Vertical Anne (prediciol Unerstry of Station (predi		ANG-4043	AngioChem Co.	Preclinical	Brain metastases	2
1201 Carrans Line Scences Inc. Carrans Line Scences Inc. 1201 GRN-1201 Genen Peptidea Co. -:S68 CT01-2688 Treamhneau Lut. -:S68 CT04-CVP Treamhneau Lut. -:C101 CT04-CVP Treamhneau Lut. -:C101 CT04-CVP Treamhneau Lut. -:C101 CT04-CVP Treamhneau Lut. -:C101 CT04-CVP Treamhneau Lut. :C101 CT04-CVP Treamhneau Lut. :C101 CT04-CVP Treamhneau Lut. :C101 CT102 Survitorin Daminopoin Pharma Co. :C101 CT102 Canonon Pharmacourticats Inc. :C101 MDL-2538 Currenean Ellopharma AS :C101 MDL-25387 Carans Capatal Con. :C101 MDL-25387 Carans Capatal Con. :C101 MDL-25387 Carans Capatal Con.	2D1 Carac Scient Cond. 2D1 Edne Nation Image Science American Condition 2D1 Edne Nation Image Science American Condition 2D2 CT01-2665 Image Science American Condition Edition Image Science American Condition Image Science American Condition Edition Image Science American Condition Image Science American Condition Edition Image Science American Condition Image Science American Condition Edition Image Science American Condition Image Science American Condition Edition Image Science American Condition Image Science American Condition Edition Image Science American Condition Image Science American Condition Edition Image Science American Condition Image Science American Condition Edition Image Science American Condition Image Science American Condition Edition Image Science American Condition Image Science American Condition Image Science American Condition Image Science American Condition Image Science American Condition Image Science American Condition Image Science American Condition Image Science American Cond	00-00-00-00-00-00-00-00-00-00-00-00-00-	MBI-226	Cadence Pharmaceuticals Inc.	=	Vulvar intraepithelial neoplasia	
1201 GRN-1201 Green Pepride Co. 1 -555 CT01-2568 Incarthrea Ltd. 1 -556 ICT03-Es5 Incarthrea Ltd. 1 -557 ICT03-Es5 Incarthrea Ltd. 1 -579 ICT04-CYP Incarthrea Ltd. 1 -571 ICT04-CYP Incarthrea Ltd. 1 -571 ICT04-CYP Incarthrea Ltd. 1 -572 ICT04-CYP Incarthrea Ltd. 1 -57 ICT04-CYP Incarthrea Ltd. 1 -55 WT-2755 Summer Danippon Pharma Co. 1 25 WT-2755 Summer Danippon Pharma Co. 1 25 UT-792 Canegut Sen Nuo Wei Bottechnology Co. 1 25 C1622 Chengdu Sen Nuo Wei Bottechnology Co. 1 26 C1622 Chengdu Sen Nuo Wei Bottechnology Co. 1 26 C1622 Chengdu Sen Nuo Wei Bottechnology Co. 1 26 C1622 Chengdu Sen Nuo We	(201 GNU-1201 Gene Reprise Cu. 1 Sold turnes 2688 CID1-568 Interview of Relationd Interview of Relationd Interview of Relationd 1 Natures granter (prochinal) Control and prochinal) Interview of Relationd E6 CID1-568 Interview of Relationd 1 Natures (prochinal) Control and prochinal) Interview of Relationd E7 CID1-569 Interview of Relationd 1 Natures (prochinal) Interview of Relationd Cr01-570 Interview of Relationd 1 Natures (prochinal) Interview of Relationd Cr01-570 Interview of Relationd 1 Natures (prochinal) Interview of Relationd Cr01-570 Interview of Relationd 1 Natures (prochinal) Interview of Relationd Control Interview of Relationd 1 Natures (prochinal) Interview of Relationd Control Interview of Relationd 1 Natures (prochinal) Interview of Relationd Control Interview of Relationd 1 Natures (prochinal) Interview of Relationd Control Interview of Relationd 1 Natures (prochinal) Interview of Relationd Control Interview of Relationd 1			Carrus Capital Corp. Cutanea Life Sciences Inc. Micenix Inc.			
-568 (T01-268) Incartinera LLd. I -565 Incartinera LLd. University of Biadford I -670 CT03-E55 Incartinera LLd. I -670 CT03-CF0 Incartinera LLd. I -671 CT03-CF0 Incartinera LLd. I -670 CT03-CF0 Incartinera LLd. I -671 CT03-CF0 Incartinera LLd. I -671 CT03-CF0 Incartinera LLd. I -671 CT03-CF0 Incurrent University of Biadford II -671 CT03-CF0 Kutome University III 55 WT-2755 Sumicomo Pharma AS I 25 WT-2755 Sumicomo Pharmacou. I 26 C1622 Caleno Pharmacou. I 27 C1622 Caleno Pharmacou. I 28 WT-2755 Sumowon Pharmacou. I 29 C1622 Caleno Pharmacou. I 29 C1622 Caleno Pharmacou. I 29 TD-1792 Caleno Pharmacou. I 201 ME-1792 Caleno Pharmacou. I 203 Dianolo TD-1792 Caleno Pharmacou. 203	-388 CT01-338 Incentine Lud Incentine Lud -561 CT01-338 Incention of Exact Incention of Exact Incent Incention of Exact Incent Incention of Exact Incent I	GRN-1201	GRN-1201	Green Peptide Co.	_	Solid tumors	>
-E55 CT03-E55 Incenthera Ltd. Incenthera Ltd. -CVP CT04-CVP Incenthera Ltd. Precincal -CVP CT04-CVP Incenthera Ltd. Incenthera Ltd. -CVP CT04-CVP Incenthera Ltd. Precincal -CVP CT04-CVP Incenthera Ltd. Incenthera Ltd. -CVP CT04-CVP Incenthera Ltd. Incenthera Ltd. -CVP CT04-CVP Incenthera Pointera Co. Incenthera Ltd. -Concol Mono/on Pharma Co. Incenthera Ltd. Incenthera Ltd. -Concol C16C2 Chengut Sen Nuo Wei Biotechnology Co. Incenthera Ltd. -Concol C16C2 Chengut Sen Nuo Wei Biotechnology Co. Incenthera Ltd. -Concol C16C2 Calara Inc. Incenteration Incenteration -Concol TD-1792 GlavoSinthKine Co. Incenteration Incenteration -C16C2 Calara Inc. Calara Inc. Incenteration Incenteration -C1100 MD-153507 Durata Threapeutics Inc. Incenteratinc.	Eise Unversity of Brachad Desite concerprecinical Eise CTCG-Eise Inversity of Brachad Concretal ensore (precinical) CrCP Inversity of Brachad Inversity of Brachad Concretal ensore (precinical) CrCP Inversity of Brachad Inversity of Brachad Inversity of Brachad CrCP Inversity of Brachad Inversity of Brachad Inversity of Brachad Inversity of Brachad Inversity of Brachad Inversity of Brachad Inversity of Brachad Inversity of Brachad Inversity of Brachad Inversity of Brachad Inversity of Brachad Inversity of Brachad Inversity of Brachad Inversity of Brachad Inversity of Brachad Inversity of Brachad Inversity of Brachad Inversity of Brachad Inversity of Brachad Inversity of Brachad Inversity of Brachad Inversity of Brachad Inversity of Brachad Inversity of Brachad Inversity of Brachad Inversity of Brachad Inversity of Brachad Inversity of Brachad Inversity of Brachad Inversity of Brachad Inversity of Brachad Inversity of Brachad Inversity of Brachad Inv	ICT01-2588	ICT01-2588	Incanthera Ltd.	_	Vascular disrupting agents	2
EIS ICT03-EIS Incenthera Ltd. I -CYP ICT04-CYP Incenthera Ltd. Pecifical -CYP ITX-315 Virk Biotherana AS I -CYP Virk Biotherana AS I I -CYP Virk Biotherana AS I I -CT5CS Sunvoicn Pharmacouticals Inc. I I -CT6C2 Chengu Sen Nuo Wei Biotechnology Co. I I -CT6C2 Chengu Sen Nuo Wei Biotechnology Co. I I -CT6C2 Chengu Sen Nuo Wei Biotechnology Co. I I -CT6C2 Chengu Sen Nuo Wei Biotechnology Co. I I -CT6C2 Chengu Sen Nuo Wei Biotechnology Co. I I -CT6C2 Chengu Sen Nuo Wei Biotechnology Co. I I -CT6C2 Chengu Sen Nuo Wei Biotechnology Co. I I -CT6C2 Chengu Sen Nuo Wei Biotechnology Co. I	ES Corroct Est Inter career (prodictal) CPD ICTOS-ES Insent Lud Productional CPD ICTOS-ES Insent Lude Productional CPD ICTOS-ES Insent Lude Productional CPS VIL2725 Surviouo Danipoon Pharma Co. I Productional CPS ICTOSE Connectal cancer (productional Insent Concertal cancer (productional CPS VIL2725 Surviouo Danipoon Pharma Co. I Pr			University of Bradford		Breast cancer (preclinical)	
E55 ICT03-E55 Incarthera Ltd. Incarthera Ltd. -CYP ICT04-CVP Incarthera Ltd. Peochnical -CYP ICT04-CVP Incarthera Ltd. Peochnical -CYP ITK-1 University of Bradford III -CYP ITK-1 EUJFLM Co. III -CYP ITK-1 EUJFLM Co. III -CYP ITK-315 Lyftx Biopharma AS I >xone TM ITX-315 Lyftx Biopharma AS I 25 WT-2725 Sumitorno Danippon Pharma Co. I 26 C1662 Chengdu Sen Nuo Wei Biotechnology Co. I 27 C1662 Chengdu Sen Nuo Wei Biotechnology Co. I 28 C1662 Chengdu Sen Nuo Wei Biotechnology Co. I 29 TD-1792 GlaxoSmithKine Co. III 201 MBI-226 Cadence Pharmaceuticals Inc. III 01 MBI-263377 Durata Threependicals Inc. III </td <td>Els Image and production Els Image and production Els Image and production CPD Image and production <td></td><td></td><td></td><td></td><td>Colorectal cancer (preclinical)</td><td></td></td>	Els Image and production Els Image and production Els Image and production CPD Image and production <td></td> <td></td> <td></td> <td></td> <td>Colorectal cancer (preclinical)</td> <td></td>					Colorectal cancer (preclinical)	
E55 ICT03-E65 Incarthera Ltd. Incarthera Ltd. -CVP ICT04-CVP Incarthera Ltd. Peclinical -CVP ICT04-CVP Incarthera Ltd. Peclinical -CVP ITK-1 FUUIFLUM Co. III Dom ^T M LTX-315 Lyttk Biopharma AS III Swithrevatiole ANG-1005 Sumitorno Datnippon Pharma Co. III 255 WT-2725 Sumitorno Datnippon Pharma Co. III 26 C1662 Chengdu Sen Nuo Wei Biotechnology Co. III 27 C1662 Cadanee Unice III 26 C1662 Cadanee Unice III 27 Cadanee Life Sciences Inc. III 28 MDL-65.367 Durat Threapeutica Inc. III 7xeit Montes Cadanee Life Sciences Inc. III 7xeit MDL-65.367 Durat Threapeutica Inc. III	ES CT03-Es6 Instance (preclineal) CPD Unvestiy of Salord I Sald turnos CPD Unvestiy of Salord Investive of Salord Investive of Salord CPD Investive of Salord Investive of Salord Investive of Salord CPD Investive of Backing Investive of Backing Investive of Backing CPD Investive of Backing Investive of Backing Investive of Backing CPD Investive of Backing Investive of Backing Investive of Backing CPD Investive of Backing Investive Investive of Backing CPD Investive Investive Investive Investive Investive Investive Investive Investive Investive Investive Investive Investive Inv					Lung cancer (preclinical)	
-Esó CT03-Esó Incanthera Ltd Incanthera Ltd -CYP ICT04-CYP Incanthera Ltd Precinical -CYP ICT04-CYP Incanthera Ltd Precinical -CYP ITK-1 University of Bradford III -CYP ITK-1 Cumensity of Bradford III -CYP ITK-1 Cumen University III -CYP Varume University III III -CYP Xurume University III III -CYP Xurume University III III -CYP Xurume University III III -Const Varume University III III -Const Varume University III III -Const Varume University III III -Const Sunvion Pharma Cu. III III -confide TD-1792 Chengu Sen Nuo Wei Biotechnology Cu. III -confide TD-1792 Chengu Sen Nuo Wei Biotechnology Cu. III -confide TD-1792 Chengu Sen Nuo Wei Biotechnology Cu. III -confide TD-1792 Chengu Sen Nuo Wei Biotechnology Cu. III -confide TD-1792 Chenge Sen Sen Sen Sen Sen Sen Sen Sen Sen Se	ess CT03-Ess Inearthrea Ltd. I Solid unersis CPP Investiy of Salod Investiy of Salod Investigentical CPP Investigentical Investigentical Investigentical CPP Investintentoco Investige					Prostate cancer (preclinical)	
-CYP Investity of Salford -CYP Icrothera Ltd. -CYP Icrothera Ltd. Imrediation University of Bradford Imrediation University of Bradford Imrediation University of Bradford Imrediation NG-1005 Sole ^{IM} ITX-315 VT2725 Sum University Sole MG-1005 Sole MG-1005 Sole MG-1005 Sole MG-1005 Sole Sumoion Pharma Co. Sole C16G2 Sole C16G2 Sole C16G2 Sole C16G2 C16G2 Chendul Sen Nuo Wel Biotechnology Co. Sole C16G2 C16G2 Chendul Sen Nuo Wel Biotechnology Co. Sole C16G2 C16G2 Chendul Sen Nuo Wel Biotechnology Co. Sole C16G2 MB-226 Chendul Sen Nuo Wel Biotechnology Co. MB-228 Cadence Pharmaceuticats Inc. MB-228 Cadence Pharmaceuticats Inc. MB-63387 Durata Therapeutics Inc. MB-63387 Durata Therapeutics Inc. MB-63387 Durata Therapeutics Inc. MB-63387 Durata Therapeutics Inc. <td>Chr Unversity of Saftod Erest carcer (precincial) c.VP CT04-CVP Inversity of Saftod Non-small cellung cancer (precincial) TK-1 Unversity of Electron Implementation Non-small cellung cancer (precincial) DomTM TK-1 Unversity of Electron Electrone Electrone TK-1 Unversity of Electron Implementation Electrone Electrone DomTM TK-315 Unversity of Electrone Electrone Electrone Saftor Unversity Implementation Electrone Electrone Saftor CTIG2 Chengdu San Nuo Wei Blatechnology Co. Implementationes Electrone Saftor CTIG2 Chengdu San Nuo Wei Blatechnology Co. Implementationes Electrone Saftor CTIG2 Chengdu San Nuo Wei Blatechnology Co. Implementationes Electrone Saftor CTIG2 Chengdu San Nuo Wei Blatechnology Co.</td> <td>ICT03-Es5</td> <td>ICT03-Es5</td> <td>Incanthera Ltd.</td> <td>_</td> <td>Solid tumors</td> <td>2</td>	Chr Unversity of Saftod Erest carcer (precincial) c.VP CT04-CVP Inversity of Saftod Non-small cellung cancer (precincial) TK-1 Unversity of Electron Implementation Non-small cellung cancer (precincial) Dom TM TK-1 Unversity of Electron Electrone Electrone TK-1 Unversity of Electron Implementation Electrone Electrone Dom TM TK-315 Unversity of Electrone Electrone Electrone Saftor Unversity Implementation Electrone Electrone Saftor CTIG2 Chengdu San Nuo Wei Blatechnology Co. Implementationes Electrone Saftor CTIG2 Chengdu San Nuo Wei Blatechnology Co. Implementationes Electrone Saftor CTIG2 Chengdu San Nuo Wei Blatechnology Co. Implementationes Electrone Saftor CTIG2 Chengdu San Nuo Wei Blatechnology Co.	ICT03-Es5	ICT03-Es5	Incanthera Ltd.	_	Solid tumors	2
CYP ICT04-CYP Incarthera Ltd Precinical ITK-1 Luinversity of Bradford University of Bradford III ITK-1 RUI-T LUinversity of Bradford III core TM ITK-1 RUI-T III core TM LTX-315 Lytix Biopharma AS III swittevatide ANG-1005 Sumiton Dainippon Pharma Co. II 25 WT-2725 Sumiton Dainippon Pharma Co. II 26 C16G2 Chengdu Sen Nuo Wei Blotechnology Co. II ancin [®] TD-1792 GlavosmithKline Co. III 26 TD-1792 GlavosmithKline Co. III 27 MBI-226 Cademoe Pharmaceuticals Inc. III 01 MBI-228 Cademoe Pharmaceuticals Inc. III ca TM MDL-63.397 Durata Life Sciences Inc. III 01 MDL-63.397 Durata Therapeutics Inc. III Pizer Inc. Durata Therapeutics Inc. III	OP ICT04-CP Inaminat Ltd. Pecifical Uverance (predincial) Int-1 EUNETUN Co. University of Baddod Badder canoer Concectal canoer Int-1 EUNETUN Co. Intersity of Baddod Intersity of Baddod Eunetsity of Baddod Int-1 EUNETUN Co. Intersity of Baddod Intersity of Baddod Eunetsity of Baddod Int-1 EUNETUN Co. Intersity of Baddod Intersity of Baddod Eunetsity of Baddod Intersity MOS-1005 MoS-1005 Intersity of Baddod Intersity of Baddod Intersity MOS-1005 MoS-1005 Intersity of Baddod Intersity of Baddod Intersity MOS-1005 Intersity of Baddod Intersity of Baddod Eliobiastona Intersity MoS-1005 Intersity of Baddod Intersity of Baddod Eliobiastona Intersity MoS-1005 Intersity of Baddod Intersity of Baddod Eliobiastona Intersity MoS-1005 Intersity of Baddod Intersity of Baddod Eliobiastona Intersity Intersity of Baddod Intersity of Baddod			University of Salford		Breast cancer (preclinical)	
CVP ICT04-CVP Insanthera Ltd. Precinical ITK-1 University of Bradfood III ITK-1 FUUIFILM Co. Green Priote Co. cone TM ITK-315 Lyrk Blopharma AS ANG-1005 AngioChem Co. I swethrevertide ANG-1005 Sumitono Dainippon Pharma Co. 25 WT-2725 Sumitono Dainippon Pharma Co. 26 C16G2 Chengdu Sen Nuo Wei Blotechnology Co. I andrin [®] TD-1792 GlavoSmithKine Co. III andrin [®] TD-1792 GlavoSmithKine Co. III 01 MBI-226 Cadence Pharmacouticals Inc. III 01 MBI-226 Cadence Pharmacouticals Inc. III ca TM MDL-63.397 Urata Therapeutics Inc. III nce TM MDL-63.397 Durata Therapeutics Inc. III	CPU CTO4-CPC Instruct and University of Bradfood Non-struct and Information Tirk-1 University of Bradfood Exclored Coorectal cancer Tirk-1 University of Bradfood III Coorectal cancer Coorectal cancer Kurum University III Coorectal cancer Swathwalds Ango/Chem Co. II Solid futurons Swathwalds Sumicon Dainipoor Planma AS II Solid futurons Swathwalds Sumicon Dainipoor Planma AS II Solid futurons Swathwalds Sumicon Dainipoor Planma AS II Solid futurons Swathwalds Sumicon Dainipoor Planma Co. II Solid futurons Swathwalds Sumicon Dainipoor Planma Co. II Brandfood cancer Swathwalds Sumicon Planma Co. II Brandfood cancer Swathwalds Sumicon Planma Co. II Brandfood cancer Swathwalds To-1792 Gavo/None Blanchroud Co. II Brandfood cancer Swathwalds To-1792 Gavo/Sumicon Blanchroud Co. II Brandfood cancer					Liver cancer (preclinical)	
-CYP (CT04-CYP Incarthera Ltd. Peclinical University of Bradford University of Bradford University of Bradford ITK-1 FUJIFILM Co. Green Peptide Co. Kurume University Statema AS UG-1005 AngoChem Co. Kurume University Statema AS UG-1005 AngoChem Co. III Contract Contract AngoChem Co. III Contract Cont	CVP ICT04-CVP Insertier LLd. Pecifical Badder cancer ITK-1 LUIFILM Co. Unresity of Badder Decinical Decinical ITK-1 LUIFILM Co. Itrg Decinical Decinical Itrk-1 LUIFILM Co. Itrk Decinical Prostate cancer Solution Itrk-1 Decinical Prostate cancer Decinical Solution Itrk-1 Decinical Prostate cancer Solution NG-1005 Itrk Brain matases Solution Survison Dainpoon Pharme Co. Itrusons Brain matases Survison Pharmeouticals inc. Itrusons Solutions Brain matases Solution To-1732 Brandoreconcerecal cancer Itrusons <					Non-small cell lung cancer (preclinical)	
Inversity of Bradford Inversity of Bradford Inversity FullFLM Co. creen Peptde Co. Kurume University Kurume University Kurume University Xume University Kurume University Xume University Kurume University Kurume University Kurume University Xume University Kurume University Xume University Kurume University Xume University Kurume University Xume University NG-1005 Xume University Indicated and an indicated an indindicated an indicated a	ITK-1 University of Bradford Colorectal cancer Caren Peptida Co. Condictal cancer Condictal cancer Caren Peptida Co. Kurune University Kurune University Condictal cancer Sold turnors MG-1005 LTX-315 Lift Co. Condictal cancer Sold turnors AngloChem Co. I Sold turnors Environe University 25 WT-2725 Survitorio Dainippon Pharma Cu. I Sold turnors Environes 26 C1662 Chengut Servitorio I Condictal cancer Environes 26 C1662 Chengut Servitorio I Dental cancer Environes 27 C1662 Chengut Servitorio I Dental cancer Environes 28 C1662 Chengut Servitorio I Dental cancer Environes 29 C1662 Chengut Servitorio I Dental cancer Environes 20 C1662 Chengut Servitorio I Dental cancer Environes 20 MBL-653.597 MBL-65.597	ICT04-CYP	ICT04-CYP	Incanthera Ltd.	Preclinical	Bladder cancer	2
ITK-1 FUJFLM Co. III Dore TM LTX-315 LUTX-315 LUTX-315 xettreveticle ANG-1005 Lytik Biopharma AS I xettreveticle ANG-1005 AngioChem Co. I 25 WT-2725 Sumitomo Dainippon Pharma Co. I 26 C1662 Chengu Sen Nuo Wei Biotechnology Co. I 2 C1662 Chengu Sen Nuo Wei Biotechnology Co. I 2 C1662 Chengu Sen Nuo Wei Biotechnology Co. I 2 C1662 Calain Inc. I ancin [®] TD-1792 GlaxoSmithKine Co. II 01 MBI-226 Cadence Pharmaceuticals Inc. II <	ITC-1 LUIFLM Co. III Colorational C			University of Bradford		Colorectal cancer	
M LTX-315 Green Peptide Co. Kurume University Luxix Biopharma AS LTX-315 Lytix Biopharma AS AngioChem Co. MajoChem Co. I NT-2725 Sumitiono Dainippon Pharma Co. I Sunovion Pharmaceuticals Inc. I C16622 Chengdu Sen Nuo Wei Biotechnology Co. I C16622 Chengdu Sen Nuo Wei Biotechnology Co. I C16622 Chengdu Sen Nuo Wei Biotechnology Co. I D1-1792 GlaxoSmithKline Co. Theravance Biopharma Inc. R-Pharm M MDI-226 Cadence Pharmaceuticals Inc. II M MDL-63,397 Durata Therapeutics Inc. II Prizer Inc.	M Invasity kurume University kurume University Prostate cancer Nume University kurume University Livit Biopharma AS I Solid turnoss MT-2735 Jupit Biopharma AS I Solid turnoss WT-2735 Sunvino Dainipono Pharma Co. I Solid turnoss WT-2735 Sunvino Pharma Cu. I Brain metastases Unicode Chengu Sen Nuo Viei Biotechnology Cu. I Dental cances Line Cried Sen Nuo Viei Biotechnology Cu. I Dental cances Line Cried Sen Nuo Viei Biotechnology Cu. I Dental cances Line Cried Viei Sen Nuo Viei Biotechnology Cu. I Dental cances Line Cried Viei Sen Nuo Viei Biotechnology Cu. I Dental cances Line Cried Viei Sen Nuo Viei	ITK-1	ITK-1	FUJIFILM Co.	=	Glioblastoma	2
M LTX-315 Kurume University I trevatide ANG-1005 Lytix Biopharma AS I trevatide ANG-1005 Sumitomo Dainippon Pharma AS I MT-2725 Sumitomo Dainippon Pharma Co. I I NT-2725 Sumitomo Dainippon Pharma Co. I I NT-2725 Sumitomo Dainippon Pharma Co. I I Sunovion Pharmaceuticals Inc. I I I Infla-1792 Chengdu Sen Nuo Wei Biotechnology Co. I I Infla-1792 GlaxoSmithKline Co. II I Infla-1792 GlaxoSmithKline Co. II III Infla-1792 GlaxoSmithKline Co. III III M MBI-226 Cadence Pharmaceuticals Inc. III III M MDL-63,397 Durata Therapeutics Inc. III III M MDL-63,397 Durata Therapeutics Inc. III III Prizer Inc. Migenix Inc. III III III	M LTX-315 Kurume University Invoide Ards-1005 Lykk Bopharma AS I Errai metastases Invoide ArgoChem Co. I Errai metastases Globiastoma WT-2725 Sunvivon Pharmacourticals inc. I Errai metastases Globiastoma WT-2725 Sunvivon Pharmacourticals inc. I Errai metastases Globiastoma University C1602 Chengdu Sen Nuo Wei Biotechnology Co. I Errained Erraines Sinformaci C1602 Chengdu Sen Nuo Wei Biotechnology Co. I Dental caries Erraines Sinformaci C1602 Chengdu Sen Nuo Wei Biotechnology Co. I Dental caries Sinformaci C3 Jain Inc. I Dental caries Erraines M TD-1732 Caelone Pharmaceuticals Inc. I Renacticals Inc. Erraines MBI-2265 Caelone Pharmaceuticals Inc. I Renacea Renacea MBI-2285 Intera Ure Sint Inc. I Renacea Renacea MBI-23397 Matant Ther			Green Peptide Co.		Prostate cancer	
Im LTX-315 Lytik Biopharma AS I trevatide ANG-1005 AngioChem Co. I WT-2725 Sumitiono Dainippon Pharma Co. I WT-2725 Sumovion Pharma Co. I Sunovion Pharma Co. Sumovion Pharma Co. I C16G2 Chengdu Sen Nuo Wei Biotechnology Co. I C16G2 Chengdu Sen Nuo Wei Biotechnology Co. I C16G2 Calan Inc. I C1792 GlaxoSmithKine Co. II M TD-1792 GlaxoSmithKine Co. II MB1-226 Cadence Pharmaceuticals Inc. III M MDL-63.397 Durata Therapeutics Inc. III M MDL-63.397 Durata Therapeutics Inc. II	IM LTX-315 Lytk Biopharma AS I Solid tumors frewatide Ards-1005 AngoChem Co. I Brain metasteses Ards-1005 AngoChem Co. I Brain metasteses Bioblestoma VT-2725 Sumition Dainippon Pharma Co. I Brain metasteses Bioblestoma VT-2725 Sumovion Pharmaceuticals Inc. I Brain metasteses Bioblestoma Solid tumos Solid tumos Bioblestoma Bioblestoma Bioblestoma Solid tumos C1652 Chengu Sen Nuo Wei Biotechnology Co. I Penadogical malignancies Solid tumos C1652 Calain Inc I Penadostesi and solid tumos Solid tumos C1652 Calain Nuo Wei Biotechnology Co. I Penadostes Dia TD-1792 Calain Inc Biotechnology Co. I Direktions Solid tumos C1652 Calain Inc Biotechnology Co. I Direktions Direktion TD-1792 Garso Explanation. I Direktions Biotechnologiotechnology Co.			Kurume University			
trevatide ANG-1005 AngioChem Co. I WT-2725 Sumovion Pharma Co. I Sunovion Pharma Co. I Cl6G2 Chengdu Sen Nuo Wei Biotechnology Co. I C16G2 Chengdu Sen Nuo Wei Biotechnology Co. I C16G2 Calian Inc C3 Jian Inc C3	Tereatide ANG-1005 AngloChem Co. I Brain metastases WT-2725 Sumitomo Dainippon Pharma Co. I Brain metastases WT-2725 Sumoton Pharma cuticats Inc. Solid turnors Clobastoma NT-2725 Chengdu Sen Nuo Wei Blotechnology Co. I Penatological melgoancias Sino TD-1792 Chengdu Sen Nuo Wei Blotechnology Co. I Dental caries Sino TD-1792 Clan More Mel Blotechnology Co. I Dental caries Sino TD-1792 Clan More Mel Blotechnology Co. I Dental caries Sino TD-1792 Clan More Mel Blotechnology Co. II Dental caries Mile TD-1792 Clan More Mel Blotechnology Co. II Dental caries Mile TD-1792 Clan More Mel Blotechnology Co. II Dental caries Mile TD-1792 Clan More Mel Blotechnology Co. II Dental caries MBI-226 Clan More Mel Blotechnology Co. III Cran Postitive Infections MBI-226 Caries Dentameacuticats Inc. III Prove wigans (I) MBI-226 Caries Caries Inc. III Prove wigans (I) MBI-2337 Mule MD-63.397 Durat Life Scincres Inc. Acre wigans (I) <	Oncopore TM	LTX-315	Lytix Biopharma AS	_	Solid tumors	2
WT-2725 Sumitomo Dainippon Pharma Co. I WT-2725 Sunovion Pharma ceuticals Inc. I Sunovion Pharmaceuticals Inc. I I C16G2 Chengdu Sen Nuo Wei Biotechnology Co. II C16G2 Changdu Sen Nuo Wei Biotechnology Co. II MB1-226 GlaxoSmithKline Co. III MB1-226 Cadence Pharmaceuticals Inc. III MB1-226 Cadence Pharmaceuticals Inc. III MB1-226 Cadence Pharmaceuticals Inc. III MB1-2337 Durata Capital Corp. III MDL-63,397 Durata Therapeutics Inc. III Pitzer Inc. Pitzer Inc. III	WT-2725 Suntomo Dainpoon Phama Cu. Including Coma Comange Coma Coma Coma Coma Coma Coma Coma Coma	Paclitaxeltrevatide	ANG-1005	AngioChem Co.	=	Brain metastases	2
WT-2725 Sumitomo Dainippon Pharma Co. I Sunovion Pharmaceuticals Inc. Sunovion Pharmaceuticals Inc. I C16G2 Chengdu Sen Nuo Wei Biotechnology Co. II C16G2 Calain Inc II C3 Jian Inc Ca Jian Inc II MB1-226 GlaxoSmithKline Co. II MB1-226 Cadence Pharmaceuticals Inc. II MB1-226 Cadence Pharmaceuticals Inc. II MB1-226 Cadence Pharmaceuticals Inc. II MB1-226 Cutanea Life Sciences Inc. II MDL-63,397 Durata Therapeutics Inc. II Prizer Inc. Prizer Inc. II	WT-2725 Sumitomo Datinipon Pharma Cu. Immediate Inc. Gioma Line Sumovion Pharmaceuticats Inc. Immediate Inc. Ciena Line Cried San Nuo Wei Biotechnology Cu. Immediate Inc. Dental carles Line Cried San Nuo Wei Biotechnology Cu. Immediate Inc. Dental carles Line Cried San Nuo Wei Biotechnology Cu. Immediate Inc. Dental carles Cience Chandra Inc. Immediate Inc. Dental carles Cience Carlan Inc. Immediate Inc. Dental carles MBI-1792 Galon Representicats Inc. Immediate Inc. Remonstrates Inc. MBI-226 Carlanee Biopharma Inc. Immediate Inc. Remonstrates Inc. MBI-226 Carlanee Infections Immediate Inc. Remonstrates Inc. MBI-228 Carlanee Infections Immediate Inc. Remonstrates Inc. MBI-2337 Undate Infections Immediate Inc. Remonstrates Inc. MMDL-63.337 Durata Interescutcats Inc. Immediate Inc. Creenviellits (Immediate Inc. MMDL-63.337 Durata Interescutcats Inc. Immediate Inc. Remonstrate Inc. MMDL-63.337 Durata Interescutcats Inc. Immediate Inc. Remonstrate Inc. MMDL-63.337 Durata Interescutcats Inc.					Glioblastoma	
WT-2725 Sumitiono Dainipon Phama Co. I Sunovion Pharmaceuticals Inc. Sunovion Pharmaceuticals Inc. I C16G2 Chengdu Sen Nuo Wei Biotechnology Co. II C16G2 Chengdu Sen Nuo Wei Biotechnology Co. II C16G2 Chengdu Sen Nuo Wei Biotechnology Co. II C16G2 Calain Inc II C3 Jian Inc Ca Jian Inc II C3 Jian Inc Calain SensithKline Co. II MB1-226 GlaxoSmithKline Co. II MB1-226 Cadence Pharmaceuticals Inc. II MB1-226 Cadence Pharmaceuticals Inc. III MB1-226 Cadence Pharmaceuticals Inc. II M MDL-63,397 Durata Therapeutics Inc. M MDL-63,397 Durata Therapeutics Inc. Prizer Inc. Prizer Inc. II	WT-2725 Sumitorio Dainipon Pharma Co. I Hematological malignancias Suld tumors Sunovion Pharmaceuticals Inc. Suld tumors Solid tumors Sunovion Pharmaceuticals Inc. I Dental caries C16G2 Chengdu Sen Nuo Wei Biotechnology Co. I Dental caries C3 Jain Inc. C3 Jain Inc. II Dental caries C4 Carian Inc. II Caries C5 C3 Jain Inc. II Caries C6 Carian Inc. II Caries C7 Carian Con. II Caries infections M MDL-63,397 Carana Life Sciences Inc. II Carana Caries Inc. M MDL-63,397 Durata Therapeutics Inc. I Osteomyeritis (I) M MDL-63,397 Durata Therapeutics Inc. I Osteomyeritis (I)					Glioma	
Sunovion Pharmaceuticals Inc. C16G2 Chengdu Sen Nuo Wei Biotechnology Co. I C16G2 Chengdu Sen Nuo Wei Biotechnology Co. I C16G2 Chengdu Sen Nuo Wei Biotechnology Co. I C3 Jian Inc C3 Jian Inc I C3 Jian Inc Calaros Biopharma Inc. II MBI-226 Cadence Pharmaceuticals Inc. II MBI-226 Cadence Pharmaceuticals Inc. II MBI-226 Cadence Pharmaceuticals Inc. II M MDL-63,397 Durata Therapeutics Inc. I Prizer Inc. Prizer Inc. I	cin [®] To-trade Suld turons cin [®] To-trade Chengdu Sen Nuo Wei Biotechnology Co. I Dental carries cin [®] To-trade Chengdu Sen Nuo Wei Biotechnology Co. I Dental carries cin [®] To-trade Clain Inc. III Dental carries Cin [®] To-trade Clain Inc. III Carries carries NaBi-226 Cachence Pharmaceuticals Inc. III Remonsitive infections Carries Cachence Pharmaceuticals Inc. III Rescea NaBi-226 Cachence Pharmaceuticals Inc. III Rescea NaBi-226 Cachence Pharmaceuticals Inc. III Acree vulgaris (II) Nabi-63,397 Durata Life Sciences Inc. III Casteo and Inference N MDL-63,397 Durata Therapeutics Inc. II Casteo and Inference IN MDL-63,397 Durata Therapeutics Inc. II Casteo and Inference IN MDL-63,397 Durata Therapeutics Inc. II Casteo and Inference IN Molecularies Inc. II Casteo and Inference Casteo and Inference IN Molecularies Inc. II Casteo and Inference Casteo and Inference IN Molecularies Inc. <td< td=""><td>WT-2725</td><td>WT-2725</td><td>Sumitomo Dainippon Pharma Co.</td><td>_</td><td>Hematological malignancies</td><td>2</td></td<>	WT-2725	WT-2725	Sumitomo Dainippon Pharma Co.	_	Hematological malignancies	2
C16G2 Chengdu Sen Nuo Wei Biotechnology Co. I cin® TD-1792 Ca Jian Inc. C3 Jian Inc. CalaxoSmithKline Co. II Theravance Biopharma Inc. Theravance Biopharma Inc. II MBI-226 Cadence Pharmaceuticals Inc. II MBI-226 Cadence Pharmaceuticals Inc. II MBI-226 Cadence Pharmaceuticals Inc. II MBI-237 Durata Life Sciences Inc. II TM MDL-63,397 Durata Therapeutics Inc. I Prizer Inc. Prizer Inc. I	Clid2 Chengdu Sen Nuo Wei Biotechnology Co. I Dental caries ciu [®] TD-1792 Chengdu Sen Nuo Wei Biotechnology Co. II Dental caries Ci 3 Jan Inc. Ci 3 Jan Inc. II Caries TD-1792 GlaxoSmithKine Co. II Carm-positive infections MBI-226 GlaxoSmithKine Co. II Carm-positive infections MBI-226 Cadence Pharmaceuticals Inc. II Carm-positive infections Carnes Capital Corp. Cadence Pharmaceuticals Inc. II Posacea MBI-226 Cadence Life Sciences Inc. II Posacea MDL-63,397 Durata Therapeutics Inc. I Catenorelites Inc. M MDL-63,397 Durata Therapeutics Inc. I Catenorelites Inc.			Sunovion Pharmaceuticals Inc.		Solid tumors	
C16G2 Chengdu Sen Nuo Wei Biotechnology Co. Il Cin [®] TD-1792 Ca Jan Inc TD-1792 GlaxoSmithKline Co. III Theravance Biopharma Inc. R-Pharm MBI-226 Cadence Pharmaceuticals Inc. III MBI-226 Cadence Pharmaceuticals Inc. III Carrus Capital Corp. Outanea Life Sciences Inc. Migenix Inc. TM MDL-63,397 Durata Therapeutics Inc. II Pfizer Inc.	C16G2 Chengdu Sen Nuo Wei Biotechnology Co. I Dental caries ci 3 Jian Inc c3 Jian Inc c3 Jian Inc c3 Jian Inc ci 3 Jian Inc GaxoSmithKline Co. II Caren-positive infections R-Pharm Inervance Biopharma Inc. II Caren-positive infections MBI-226 Cadence Pharmaceuticals Inc. II Renaccions MBI-226 Cadence Pharmaceuticals Inc. II Roacea MDL-83,397 Uutana Life Sciences Inc. II Reacea M MDL-83,397 Durata Therapeutics Inc. I Carena Vigaris (I) TM MDL-83,397 Durata Therapeutics Inc. I Carena Vigaris (I) TM MDL-83,397 Durata Therapeutics Inc. I Carena Vigaris (I) TM MDL-83,397 Durata Therapeutics Inc. I Carena Vigaris (I) TM MDL-83,397 Durata Therapeutics Inc. I Carena Vigaris (I) TM MDL-83,397 Durata Therapeutics Inc. I Carena Vigaris (I) TM MDL-83,397 Durata Therapeutics Inc. I Careomyetitis (I)	AMPs					
cin [®] TD-1792 GlaxoSmithKline Co. III Theravance Biopharma Inc. III R-Pharm MBI-226 Cadence Pharmaceuticals Inc. III Carrus Capital Corp. Carrus Capital Corp. Cutanea Life Sciences Inc. Migenk Inc. III Pfizer Inc. III	Cid Jan Inc Cid Jan Inc Cid Montrial Inc. In D-1792 GlaxoSmithKline Co. Theravance Biopharma Inc. Theravance Biopharma Inc. Skin and soft tissue infections R-Pharm R-Pharm Ren-positive infections MBI-226 Cadence Pharmaceuticals Inc. III Resacca MBI-226 Cadence Pharmaceuticals Inc. III Rosacca MBI-226 Cadence Pharmaceuticals Inc. III Rosacca MBI-226 Cadence Pharmaceuticals Inc. III Rosacca MBI-226 Cadence Pharmaceuticals Inc. III Acne vulgaris (II) MBI-226 Cutanea Life Sciences Inc. II Acne vulgaris (II) Migenix Inc. II Osteomyelitis (I) MID-63,397 Durata Therapeutics Inc. II Osteomyelitis (I) Migenix Inc. II Osteomyelitis (I) Osteomyelitis (I)	C16G2	C16G2	Chengdu Sen Nuo Wei Biotechnology Co.	=	Dental caries	Topical
cin ⁽⁶⁾ TD-1792 GlaxoSmithKline Co. III Theravance Biopharma Inc. Theravance Biopharma Inc. R-Pharm MBI-226 Cadence Pharmaceuticals Inc. III Carrus Capital Corp. Carrus Capital Corp. Cutanea Life Sciences Inc. Migenk Inc. IM MDL-63,397 Durata Therapeutics Inc. II	cin ^(a) TD-1792 GlaxoSmithKline Co. III Gram-positive infections Theravance Biopharma Inc. Theravance Biopharma Inc. Reham R-Pham MBI-226 Cadence Pharmaceuticals Inc. III Resacea Carrus Capital Corp. <i>Acne vulgaris</i> (II) Cutanea Life Sciences Inc. III Acne <i>vulgaris</i> (II) Migenix Inc. III Costeomyalitis Migenix Inc. II Osteomyalitis (I) Prizer Inc. III Osteomyalitis (I) Vicuron Pharmaceuticals Inc. Phermonia (preclinical)	(C3 Jian Inc			
Theravance Biopharma Inc. R-Pharm MBI-226 Cadence Pharmaceuticals Inc. III Carrus Capital Corp. Curtanea Life Sciences Inc. Migenix Inc. III MDL-63,397 Durata Therapeutics Inc. II Pfizer Inc.	The ravance Biopharma Inc. Skin and soft tissue infections R-Pharm R-Pharm R-Pharm III R-Pharm Resacces Cadence Pharmaceuticals Inc. III Resacces Acne vulgaris (II) Catranea Life Sciences Inc. Acne vulgaris (II) M MDL-63,397 Durata Therapeutics Inc. M MDL-63,397 Durata Therapeutics Inc. TM MDL-63,397 Durata Therapeutics Inc. TM MDL-63,397 Durata Therapeutics Inc.	Cefilavancin [®]	TD-1792	GlaxoSmithKline Co.	=	Gram-positive infections	Topical
TM R-Pham MBI-226 Cadence Pharmaceuticals Inc. Carrus Capital Corp. III Cutanea Life Sciences Inc. Migenix Inc. MDL-63,397 Durata Therapeutics Inc. TM MDL-63,397	R-Pham R-Pham MBI-226 Cadence Pharmaceuticals Inc. II Rosacea Carrus Capital Corp. Carrus Capital Corp. Acne vulgaris (II) Cutanea Life Sciences Inc. Morean Marts (II) Acne vulgaris (II) M MDL-63,397 Durata Therapeutics Inc. II Osteomyelitis (II) TM MDL-63,397 Durata Therapeutics Inc. II Osteomyelitis (II) TM MDL-63,397 Durata Therapeutics Inc. II Osteomyelitis (II) TM MDL-63,397 Durata Therapeutics Inc. II Osteomyelitis (II)			Theravance Biopharma Inc.		Skin and soft tissue infections	
MBI-226 Cadence Pharmaceuticals Inc. III Carrus Capital Corp. Curtanea Life Sciences Inc. Migenix Inc. IM MDL-63,397 Durata Therapeutics Inc. II Pfizer Inc.	MBI-226 Cadence Pharmaceuticals Inc. II Rosacea Carrus Capital Corp. Carrus Capital Corp. Acre vulgaris (II) Cutanea Life Sciences Inc. Acre vulgaris (II) Acre vulgaris (II) M MDL-63,397 Durata Therapeutics Inc. II Osteomyelitis (I) TM MDL-63,397 Durata Therapeutics Inc. II Osteomyelitis (I) TM MDL-63,397 Durata Therapeutics Inc. II Osteomyelitis (I) TM Vicuron Pharmaceuticals Inc. Phermonia (preclinical)			R-Pharm			
Carrus Capital Corp. Cutanea Life Sciences Inc. Migenix Inc. MDL-63,397 Durata Therapeutics Inc. II Pfizer Inc.	Carrus Capital Corp. Acne vulgaris (II) Cutanea Life Sciences Inc. Genital warts (I) Migenix Inc. II MDL-63,397 Durata Therapeutics Inc. MDL-63,397 Durata Therapeutics Inc. Pfizer Inc. II Yicuron Pharmaceuticals Inc. Osteomyelitis (I) Vicuron Pharmaceuticals Inc. Pneumonia (preclinical)	CLS-001	MBI-226	Cadence Pharmaceuticals Inc.	=	Rosacea	Topical
Outanea Life Sciences Inc. Migenix Inc. MDL-63,397 Durata Therapeutics Inc. II Pfizer Inc.	Outanea Life Sciences Inc. Genital warts (I) Migenix Inc. II MDL-63,397 Durata Therapeutics Inc. MDL-63,397 Durata Therapeutics Inc. Pfizer Inc. II Vicuron Pharmaceuticals Inc. Pheumonia (preclinical)			Carrus Capital Corp.		Acne vulgaris (II)	
Migenix Inc. MDL-63,397 Durata Therapeutics Inc. Pfizer Inc.	Migenix Inc. II Osteomyelitis MDL-63,397 Durata Therapeutics Inc. II Osteomyelitis Pfizer Inc. Osteomyelitis (I) Vicuron Pharmaceuticals Inc.			Cutanea Life Sciences Inc.		Genital warts (II)	
MDL-63,397 Durata Therapeutics Inc. Pfizer Inc.	MDL-63,397 Durata Therapeutics Inc. II Osteonryelitis Pfizer Inc. Osteonryelitis (I) Vicuron Pharmaceuticals Inc. Pneumonia (preclinical)			Migenix Inc.			
		Dalvance TM	MDL-63,397	Durata Therapeutics Inc.	=	Osteomyelitis	\geq
				Pfizer Inc.		Osteomyelitis (I)	
				Vicuron Pharmaceuticals Inc.		Pneumonia (preclinical)	

5

Product name	Peptide	Company	Highest phase	Condition treated	Route of administration
DPK-060	DPK-060	DermaGen AB	=	Atopic dermatitis	Topical
		Pergamum AB		Otitis externa	
		Karolinska Development AB			
LL-37	LL-37	Pergamum AB	=	Leg ulcer	Topical
		Karolinska Development AB			
Locilex [®]	MSI-78	Dipexium Pharmaceuticals Inc.	=	Diabetic foot ulcer	Topical
		Genaera Corp.		Skin and soft tissue infections (I)	
		GlaxoSmithKline Plc.			
		RRD International Inc.			
Luminaderm [®]	NP108	NovaBiotics Ltd.	_	Bovine mastitis	Topical
Lytixar TM	LTX109	Lytix Biopharma AS	=	Impetigo	Topical
				Staphylococcus aureus infections	
Murepavadin [®]	POL-7080	Polyphor Ltd.	=	Pseudomonas aeruginosa infections	>
		University of Zurich		Gram-negative infections (I)	
Novamycin [®]	NP-339	NovaBiotics Ltd.	_	Cystic fibrosis	2
				Invasive fungal disease	
				Oropharyngeal candidiasis	
Novarifyn [®]	NP-432	NovaBiotics Ltd.	Preclinical	Methicillin-resistant <i>Staphylococcus</i> aureus (MRSA) <i>P. aeruginosa</i>	≥
				C. difficile infections	
Novexatin®	NP-213	NovaBiotics Ltd.	_	Onychomycosis	Topical
		Taro Pharmaceutical Industries Ltd.			
NVB302	NVB302	Novacta Biosystems Ltd.	_	C. difficile infections	Topical
PXL-01	Lactoferrin	DermaGen AB	=	Post-surgical adhesions	Topical
		Karolinska Development AB			
		PharmaSurgics AB			
		Promore Pharma			
		Pergamum AB			
SGX-942	Dusquetide	Inimex Pharmaceuticals Inc.	Preclinical	Melioidosis	\geq
		SciClone Pharmaceuticals Inc.			
		Soligenix Inc.			
		University of British Columbia			
Surotomycin	MK-4261	Cubist Pharmaceuticals Inc.	=	Clostridium difficile infections	\geq
		Merck & Co. Inc.			
Telavancin [®]	TD-6424	Clinigen Group plc	=	Osteomyelitis	>
		Innoviva Inc.		Bacterial infections (I)	
		Pendopharm			
		Theravance Biopharma Inc.			
		I laivaraity of Illinaio			

6

February 2017 | Volume 5 | Article 5

them improved therapeutic activity and pharmaceutic design (Chen et al., 2005; Uggerhøj et al., 2015; Kang et al., 2017).

CONCLUSION AND FUTURE DIRECTIONS

In conclusion, AMPs and ACPs have been known for several decades, but only in the last one an increasing number of publications on thier in vivo activities has arisen. Consequently, few peptides are used in medical practice. However, we believe that in the upcoming years peptides will have a major impact on the treatment of infectious diseases and cancer, two of the world's greatest healthcare concerns. As shown here, different microbial infections and/or cancer-targeting peptides are in clinical trials, with approval for clinical application expected for the next few years (at least 10 in the next 5 years). Moreover, that number should tend to increase due to advances in the rational design of peptides, minimizing or eliminating cytotoxic effects. In addition, advances in the large-scale synthesis of peptides has made this process cheaper, thus making peptidebased therapies likely to become more accessible to patients. Another strategy that has gained attention is the combined use of peptides with conventional drugs, which reduces costs per treatment, minimizing the problem of resistance and preventing recurrence. Thus, AMPs and ACPs have great potential, both

REFERENCES

- Andreu, D., and Rivas, L. (1998). Animal antimicrobial peptides: an overview. *Biopolymers* 47, 415–433.
- Arias, C. A., and Murray, B. E. (2009). Antibiotic-resistant bugs in the 21st Century — a clinical super-challenge. N.Engl. J. Med. 360, 439–443. doi: 10.1056/NEJMp0804651
- Arnold, M., Karim-Kos, H. E., Coebergh, J. W., Byrnes, G., Antilla, A., Ferlay, J., et al. (2015). Recent trends in incidence of five common cancers in 26 European countries since 1988: analysis of the European Cancer Observatory. *Eur. J. Cancer* 51, 1164–1187. doi: 10.1016/j.ejca.2013.09.002
- Attiê, R. (2014). Acute bacterial infection negatively impacts cancer specific survival of colorectal cancer patients. World J. Gastroenterol. 20:13930. doi: 10.3748/wjg.v20.i38.13930
- Baguley, B. C. (2010). Multiple drug resistance mechanisms in Cancer. Mol. Biotechnol. 46, 308–316. doi: 10.1007/s12033-010-9321-2
- Bevers, E. M., Confurius, P., and Zwaal, R. F. (1996). Regulatory mechanisms in maintenance and modulation of transmembrane lipid asymmetry: pathophysiological implicationspub.Com/. *Lupus* 5, 480–487.
- Chen, Y., Mant, C. T., Farmer, S. W., Hancock, R. E. W., Vasil, M. L., and Hodges, R. S. (2005). Rational design of alpha-helical antimicrobial peptides with enhanced activities and specificity/therapeutic index. *J. Biol. Chem.* 280, 12316–12329. doi: 10.1074/jbc.M413406200
- Dąbrowska, K., Kaźmierczak, Z., Majewska, J., Miernikiewicz, P., Piotrowicz, A., Wietrzyk, J., et al. (2014). Bacteriophages displaying anticancer peptides in combined antibacterial and anticancer treatment. *Future Microbiol.* 9, 861–869. doi: 10.2217/fmb.14.50
- de la Fuente-Núñez, C., Reffuveille, F., Mansour, S. C., Reckseidler-Zenteno, S. L., Hernández, D., Brackman, G., et al. (2015). D-enantiomeric peptides that eradicate wild-type and multidrug-resistant biofilms and protect against lethal *Pseudomonas aeruginosa* infections. *Chem. Biol.* 22, 196–205. doi: 10.1016/j.chembiol.2015.01.002
- Dennison, S. R., Harris, F., Bhatt, T., Singh, J., and Phoenix, D. A. (2010). A theoretical analysis of secondary structural characteristics of anticancer peptides. *Mol. Cell. Biochem.* 333, 129–135. doi: 10.1007/s11010-009-0213-3

alone and in combination with conventional drugs, to be used in infection and cancer therapies, mostly due to their effective mechanisms of action on the target cells.

AUTHOR CONTRIBUTIONS

MF, OS, SG, and NS wrote the article. SG, NS, and OF reviewed the article.

ACKNOWLEDGMENTS

This work was supported by Fundação para a Ciência e a Tecnologia – Ministério da Ciência, Tecnologia e Ensino Superior (FCT-MCTES, Portugal), by Brazilian funding agencies CNPq, CAPES, FADPDF, FINEP, and FUNDECT, and by Marie Skłodowska-Curie, Research, and Innovation Staff Exchange (MSCA-RISE, European Union) project INPACT (call H2020-MSCA-RISE-2014, grant agreement 644167). MF acknowledges FCT-MCTES fellowship SPRH/BD/100517/2014. OS holds a postdoctoral scholarship from the National Council of Technological and Scientific Development (CNPq) and Fundação de Apoio ao Desenvolvimento do Ensino, Ciência e Tecnologia do Estado de Mato Grosso do Sul (FUNDECT; 300583/2016-8).

- Dennison, S. R., Harris, F., and Phoenix, D. A. (2007). The interactions of aurein 1.2 with cancer cell membranes. *Biophys. Chem.* 127, 78–83. doi: 10.1016/j.bpc.2006.12.009
- Dennison, S., Whittaker, M., Harris, F., and Phoenix, D. (2006). Anticancer alpha-helical peptides and structure/function relationships underpinning their interactions with tumour cell membranes. *Curr. Protein Pept. Sci.* 7, 487–499. doi: 10.2174/138920306779025611
- Domalaon, R., Findlay, B., Ogunsina, M., Arthur, G., and Schweizer, F. (2016). Ultrashort cationic lipopeptides and lipopeptoids: evaluation and mechanistic insights against epithelial cancer cells. *Peptides* 84, 58–67. doi: 10.1016/j.peptides.2016.07.007
- Drusano, G. L. (2004). Antimicrobial pharmacodynamics: critical interactions of "bug and drug." *Nat. Rev. Microbiol.* 2, 289–300. doi: 10.1038/nrmicro862
- Ferlay, J., Shin, H.-R., Bray, F., Forman, D., Mathers, C., and Parkin, D. M. (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127, 2893–2917. doi: 10.1002/ijc.25516
- Ferlay, J., Steliarova-Foucher, E., Lortet-Tieulent, J., Rosso, S., Coebergh, J. W. W., Comber, H., et al. (2013). Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. *Eur. J. Cancer* 49, 1374–1403. doi: 10.1016/j.ejca.2012.12.027
- Figueiredo, C. R., Matsuo, A. L., Massaoka, M. H., Polonelli, L., and Travassos, L. R. (2014). Anti-tumor activities of peptides corresponding to conserved complementary determining regions from different immunoglobulins. *Peptides* 59, 14–19. doi: 10.1016/j.peptides.2014.06.007
- Fishman, J. A. (2011). Infections in immunocompromised hosts and organ transplant recipients: essentials. *Liver Transplant*. 17, S34–S37. doi: 10.1002/lt.22378
- Furlong, S., Mader, J., and Hoskin, D. (2006). Lactoferricin-induced apoptosis in estrogen-nonresponsive MDA-MB-435 breast cancer cells is enhanced by C6 ceramide or tamoxifen. Oncol. Rep. 15, 1385–1390. doi: 10.3892/or.15. 5.1385
- Gaspar, D., Freire, J. M., Pacheco, T. R., Barata, J. T., and Castanho, M. A. R. B. (2015). Apoptotic human neutrophil peptide-1 anti-tumor activity revealed by cellular biomechanics. *Biochim. Biophys. Acta Mol. Cell Res.* 1853, 308–316. doi: 10.1016/j.bbamcr.2014.11.006

- Gaspar, D., Veiga, A. S., and Castanho, M. A. (2013). From antimicrobial to anticancer peptides. A review. *Front. Microbiol.* 4:294. doi: 10.3389/fmicb.2013.00294
- Gaspar, D., Veiga, A. S., Sinthuvanich, C., Schneider, J. P., and Castanho, M. A. R. B. (2012). Anticancer peptide SVS-1: efficacy precedes membrane neutralization. *Biochemistry* 51, 6263–6265. doi: 10.1021/bi300836r
- Giacometti, A., Cirioni, O., Riva, A., Kamysz, W., Silvestri, C., Nadolski, P., et al. (2007). *In vitro* activity of aurein 1.2 alone and in combination with antibiotics against gram-positive nosocomial cocci. *Antimicrob. Agents Chemother.* 51, 1494–1496. doi: 10.1128/AAC.00666-06
- Gordon, Y. J., Romanowski, E. G., and McDermott, A. M. (2005). A review of antimicrobial peptides and their therapeutic potential as anti-infective drugs. *Curr. Eye Res.* 30, 505–515. doi: 10.1080/02713680590968637
- Hamman, J. H., Enslin, G. M., and Kotzé, A. F. (2005). Oral delivery of peptide drugs: barriers and developments. *BioDrugs* 19, 165–177. doi: 10.2165/00063030-200519030-00003
- Hancock, R. E. (1997). Peptide antibiotics. Lancet 349, 418–422. doi: 10.1016/S0140-6736(97)80051-7
- Hancock, R. E., Haney, E. F., and Gill, E. E. (2016). The immunology of host defence peptides: beyond antimicrobial activity. *Nat. Rev. Immunol.* 16, 321–334. doi: 10.1038/nri.2016.29
- Hao, X., Yan, Q., Zhao, J., Wang, W., Huang, Y., and Chen, Y. (2015). TAT modification of alpha-helical anticancer peptides to improve specificity and efficacy. *PLoS ONE* 10:e0138911. doi: 10.1371/journal.pone.0138911
- Hicks, R. P. (2016). Antibacterial and anticancer activity of a series of novel peptides incorporating cyclic tetra-substituted C α amino acids. *Bioorg. Med. Chem.* 24, 4056–4065. doi: 10.1016/j.bmc.2016.06.048
- Hilchie, A. L., Doucette, C. D., Pinto, D. M., Patrzykat, A., Douglas, S., and Hoskin, D. W. (2011). Pleurocidin-family cationic antimicrobial peptides are cytolytic for breast carcinoma cells and prevent growth of tumor xenografts. *Breast Cancer Res.* 13, R102. doi: 10.1186/bcr3043
- Hoskin, D. W., and Ramamoorthy, A. (2008). Studies on anticancer activities of antimicrobial peptides. *Biochim. Biophys. Acta Biomembr.* 1778, 357–375. doi: 10.1016/j.bbamem.2007.11.008
- Huang, Y. B., Wang, X. F., Wang, H. Y., Liu, Y., and Chen, Y. (2011). Studies on mechanism of action of anticancer peptides by modulation of hydrophobicity within a defined structural framework. *Mol. Cancer Ther.* 10, 416–426. doi: 10.1158/1535-7163.MCT-10-0811
- Jenssen, H., Hamill, P., and Hancock, R. E. W. (2006). Peptide antimicrobial agents. *Clin. Microbiol. Rev.* 19, 491–511. doi: 10.1128/CMR.00056-05
- Kakde, D., Jain, D., Shrivastava, V., Kakde, R., and Patil, A. T. (2011). Cancer therapeutics-opportunities, challenges and advances in drug delivery. J. Appl. Pharm. Sci. 1, 1–10.
- Kang, H. K., Kim, C., Seo, C. H., and Park, Y. (2017). The therapeutic applications of antimicrobial peptides (AMPs): a patent review. J. Microbiol. 55, 1–12. doi: 10.1007/s12275-017-6452-1
- Kao, C., Lin, X., Yi, G., Zhang, Y., Rowe-Magnus, D. A., and Bush, K. (2016). Cathelicidin antimicrobial peptides with reduced activation of toll-like receptor signaling have potent bactericidal activity against colistin-resistant bacteria. *MBio* 7, e01418–16. doi: 10.1128/mBio.01418-16
- Kelly, G. J., Kia, A. F.-A., Hassan, F., O'Grady, S., Morgan, M. P., Creaven, B. S., et al. (2016). Polymeric prodrug combination to exploit the therapeutic potential of antimicrobial peptides against cancer cells. *Org. Biomol. Chem.* 14, 9278–9286. doi: 10.1039/C6OB01815G
- Kwok, P. C., Grabarek, A., Chow, M. Y., Lan, Y., Li, J. C., Casettari, L., et al. (2015). Inhalable spray-dried formulation of D-LAK antimicrobial peptides targeting tuberculosis. *Int. J. Pharm.* 491, 367–374. doi: 10.1016/j.ijpharm.2015.07.001
- Lan, Y., Lam, J. T., Siu, G. K., Yam, W. C., Mason, A. J., and Lam, J. K. (2014). Cationic amphipathic D-enantiomeric antimicrobial peptides with *in vitro* and *ex vivo* activity against drug-resistant *Mycobacterium tuberculosis*. *Tuberculosis* 94, 678–689. doi: 10.1016/j.tube.2014.08.001
- Lee, H. S., Park, C. B., Kim, J. M., Jang, S. A., Park, I. Y., Kim, M. S., et al. (2008). Mechanism of anticancer activity of buforin IIb, a histone H2A-derived peptide. *Cancer Lett.* 271, 47–55. doi: 10.1016/j.canlet.2008.05.041
- Lin, Y. C., Lim, Y. F., Russo, E., Schneider, P., Bolliger, L., Edenharter, A., et al. (2015). Multidimensional design of anticancer peptides. *Angew. Chemie Int. Ed.* 54, 10370–10374. doi: 10.1002/anie.201504018

- Lincke, C. R., van der Bliek, A., M., Schuurhuis, G. J., van der Velde-Koerts, T., Smit, J. J., and Borst, P. (1990). Multidrug resistance phenotype of human BRO melanoma cells transfected with a wild-type human mdr1 complementary DNA. *Cancer Res.* 50, 1779–1785.
- Mader, J. S., and Hoskin, D. W. (2006). Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatment. *Expert Opin. Investig. Drugs* 15, 933–946. doi: 10.1517/13543784.15.8.933
- Mandell, L. A., Ball, P., and Tillotson, G. (2001). Antimicrobial safety and tolerability: differences and dilemmas. *Clin. Infect. Dis.* 32, S72–S79. doi: 10.1086/319379
- Mansour, S. C., Pletzer, D., de la Fuente-Núñez, C., Kim, P., Cheung, G. Y., Joo, H.-S., et al. (2016). Bacterial abscess formation is controlled by the stringent stress response and can be targeted therapeutically. *EBioMedicine* 12, 219–226. doi: 10.1016/j.ebiom.2016.09.015
- McKenna, M. (2013). Antibiotic resistance: the last resort. *Nature* 499, 394–396. doi: 10.1038/499394a
- McKeown, S. T. W., Lundy, F. T., Nelson, J., Lockhart, D., Irwin, C. R., Cowan, C. G., et al. (2006). The cytotoxic effects of human neutrophil peptide-1 (HNP1) and lactoferrin on oral squamous cell carcinoma (OSCC) *in vitro*. *Oral Oncol.* 42, 685–690. doi: 10.1016/j.oraloncology.2005.11.005
- Melo, M. N., Ferre, R., Feliu, L., Bardají, E., Planas, M., and Castanho, M. A. R. B. (2011). Prediction of antibacterial activity from physicochemical properties of antimicrobial peptides. *PLoS ONE* 6:e28549. doi: 10.1371/journal.pone.0028549
- Nishimura, M., Abiko, Y., Kurashige, Y., Takeshima, M., Yamazaki, M., Kusano, K., et al. (2004). Effect of defensin peptides on eukaryotic cells: primary epithelial cells, fibroblasts and squamous cell carcinoma cell lines. *J. Dermatol. Sci.* 36, 87–95. doi: 10.1016/j.jdermsci.2004.07.001
- Papo, N., and Shai, Y. (2005). Host defense peptides as new weapons in cancer treatment. *Cell. Mol. Life Sci.* 62, 784–790. doi: 10.1007/s00018-005-4560-2
- Paredes-Gamero, E. J., Martins, M. N. C., Cappabianco, F. A. M., Ide, J. S., and Miranda, A. (2012). Characterization of dual effects induced by antimicrobial peptides: regulated cell death or membrane disruption. *Biochim. Biophys. Acta* 1820, 1062–1072. doi: 10.1016/j.bbagen.2012.02.015
- Park, C. B., Kim, H. S., and Kim, S. C. (1998). Mechanism of action of the antimicrobial peptide buforin II: buforin II kills microorganisms by penetrating the cell membrane and inhibiting cellular functions. *Biochem. Biophys. Res. Commun.* 244, 253–257. doi: 10.1006/bbrc.1998.8159
- Parkin, D. M. (2006). The global health burden of infection-associated cancers in the year 2002. *Int. J. Cancer* 118, 3030–3044. doi: 10.1002/ijc.21731
- Patrzykat, A., Gallant, J. W., Seo, J., Pytyck, J., and Douglas, S. E. (2003). Novel antimicrobial peptides derived from flatfish genes. *Antimicrob. Agents Chemother*. 47, 2464–2470. doi: 10.1128/AAC.47.8.2464-2470.2003
- Renukuntla, J., Vadlapudi, A. D., Patel, A., Boddu, S. H., and Mitra, A. K. (2013). Approaches for enhancing oral bioavailability of peptides and proteins. *Int. J. Pharm.* 447, 75–93. doi: 10.1016/j.ijpharm.2013.02.030
- Riedl, S., Zweytick, D., and Lohner, K. (2011). Membrane-active host defense peptides – challenges and perspectives for the development of novel anticancer drugs. *Chem. Phys. Lipids* 164, 766–781. doi: 10.1016/j.chemphyslip.2011.09.004
- Rolston, K. V. (2001). The spectrum of pulmonary infections in cancer patients. *Curr. Opin. Oncol.* 13, 218–223. doi: 10.1097/00001622-200107000-00002
- Rozek, T., Wegener, K. L., Bowie, J. H., Olver, I. N., Carver, J. A., Wallace, J. C., et al. (2000). The antibiotic and anticancer active aurein peptides from the Australian bell frogs *Litoria aurea* and *Litoria raniformis*. *Eur. J. Biochem.* 267, 5330–5341. doi: 10.1046/j.1432-1327.2000.01536.x
- Schweizer, F. (2009). Cationic amphiphilic peptides with cancer-selective toxicity. *Eur. J. Pharmacol.* 625, 190–194. doi: 10.1016/j.ejphar.2009.08.043
- Segura, C., Guzmán, F., Salazar, L. M., Patarroyo, M. E., Orduz, S., and Lemeshko, V. (2007). btm-p1 polycationic peptide biological activity and 3D-dimensional structure. *Biochem. Biophys. Res. Commun.* 353, 908–914. doi: 10.1016/j.bbrc.2006.12.113
- Sinthuvanich, C., Veiga, A. S., Gupta, K., Gaspar, D., Blumenthal, R., and Schneider, J. P. (2012). Anticancer β -hairpin peptides: membraneinduced folding triggers activity. *J. Am. Chem. Soc.* 134, 6210–6217. doi: 10.1021/ja210569f

- Smith, L. L., and White, I. N. H. (1995). Chemoprevention of breast cancer by tamoxifen: risks and opportunities. *Toxicol. Lett.* 82–83, 181–186. doi: 10.1016/0378-4274(95)03476-5
- Theuretzbacher, U. (2012). Accelerating resistance, inadequate antibacterial drug pipelines and international responses. *Int. J. Antimicrob. Agents* 39, 295–299. doi: 10.1016/j.ijantimicag.2011.12.006
- Thundimadathil, J. (2012). Cancer treatment using peptides: current therapies and future prospects. J. Amino Acids 2012, 1–13. doi: 10.1155/2012/967347
- Tørfoss, V., Ausbacher, D., Cavalcanti-Jacobsen, C. de A., Hansen, T., Brandsdal, B. O., Havelkova, M., et al. (2012a). Synthesis of anticancer heptapeptides containing a unique lipophilic β2,2-amino acid building block. J. Pept. Sci. 18, 170–176. doi: 10.1002/psc.1434
- Tørfoss, V., Isaksson, J., Ausbacher, D., Brandsdal, B.-O., Flaten, G. E., Anderssen, T., et al. (2012b). Improved anticancer potency by head-to-tail cyclization of short cationic anticancer peptides containing a lipophilic β 2,2 -amino acid. *J. Pept. Sci.* 18, 609–619. doi: 10.1002/psc.2441
- Tyagi, A., Kapoor, P., Kumar, R., Chaudhary, K., Gautam, A., and Raghava, G. P. S. (2013). *In silico* models for designing and discovering novel anticancer peptides. *Sci. Rep.* 3:2984. doi: 10.1038/srep02984
- Uggerhøj, L. E., Poulsen, T. J., Munk, J. K., Fredborg, M., Sondergaard, T. E., Frimodt-Moller, N., et al. (2015). Rational design of alphahelical antimicrobial peptides: do's and don'ts. *ChemBioChem* 16, 242–253. doi: 10.1002/cbic.201402581
- Varkey, J., and Nagaraj, R. (2005). Antibacterial activity of human neutrophil defensin HNP-1 analogs without cysteines. *Antimicrob. Agents Chemother*. 49, 4561–4566. doi: 10.1128/AAC.49.11.4561-4566.2005
- Vedham, V., Divi, R. L., Starks, V. L., and Verma, M. (2014). Multiple infections and cancer: implications in epidemiology. *Technol. Cancer Res. Treat.* 13, 177–194. doi: 10.7785/tcrt.2012.500366

- Wang, K.-r., Yan, J. X., Zhang, B. Z., Song, J. J., Jia, P. F., and Wang, R. (2009). Novel mode of action of polybia-MPI, a novel antimicrobial peptide, in multi-drug resistant leukemic cells. *Cancer Lett.* 278, 65–72. doi: 10.1016/j.canlet.2008.12.027
- Wang, Y.-s., Li, D., Shi, H. S., Wen, Y. J., Yang, L., Xu, N., et al. (2009). Intratumoral expression of mature human neutrophil peptide-1 mediates antitumor immunity in mice. *Clin. Cancer Res.* 15, 6901–6911. doi: 10.1158/1078-0432.CCR-09-0484
- Wu, D., Gao, Y., Qi, Y., Chen, L., Ma, Y., and Li, Y. (2014). Peptidebased cancer therapy: opportunity and challenge. *Cancer Lett.* 351, 13–22. doi: 10.1016/j.canlet.2014.05.002
- Xiao, Y. F., Jie, M. M., Li, B. S., Hu, C. J., Xie, R., Tang, B., et al. (2015). Peptidebased treatment: a promising cancer therapy. *J. Immunol. Res.* 2015, 1–13. doi: 10.1155/2015/761820
- Xu, N., Wang, Y. S., Pan, W. B., Xiao, B., Wen, Y. J., Chen, X. C., et al. (2008). Human alpha-defensin-1 inhibits growth of human lung adenocarcinoma xenograft in nude mice. *Mol. Cancer Ther.* 7, 1588–1597. doi: 10.1158/1535-7163.MCT-08-0010

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2017 Felício, Silva, Gonçalves, Santos and Franco. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.